[Evidence for the action of raubasine from a new formulation of Lamuran tablets].
It was possible in a controlled double-blind study to demonstrate by means of dynamographic measurements the action of raubasine in patients with cerebrovascular disorders. A new formulation of Lamuran tablets (MF706d) was used for the investigation. This formulation has an improved in-vitro dissolution rate for raubasine that is largely independent of pH. In the raubasine group (10 patients aged 47 to 81 years, including 6 cases of anacidity) there was after one and two weeks treatment with dialy doses of 90 mg raubasine a significant reduction of the raised vascular resistance and pulsewave velocity and systolic blood pressure in the internal carotid artery which indicate an improvement in cerebral haemodynamics. In contrast, no significant changes in these parameters could be found in the placebo group (9 patients aged 52 to 83 years). The therapeutic relevance of the haemodynamic effects was supported by a simultaneous clinical improvement.
D000126:Achlorhydria / Q000503:physiopathology; D000284:Administration, Oral; D000368:Aged; D001682:Biological Availability; D001794:Blood Pressure / Q000187:drug effects; D002343:Carotid Artery, Internal / Q000503:physiopathology; D002561:Cerebrovascular Disorders / Q000188:drug therapy / Q000503:physiopathology; D002986:Clinical Trials as Topic; D004339:Drug Compounding; D006801:Humans; D008875:Middle Aged; D010919:Placebos; D011674:Pulse / Q000187:drug effects; D046948:Secologanin Tryptamine Alkaloids / Q000627:therapeutic use; D014655:Vascular Resistance / Q000187:drug effects; D015016:Yohimbine
D010919:Placebos; D046948:Secologanin Tryptamine Alkaloids; D015016:Yohimbine; C005709:raubasine
Wirkungsnachweis von Raubasin aus einer neuen Rezeptur von Lamuran -Dragees